Beijing SL Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio
Beijing SL Pharmaceutical Co Ltd cash flow-to-debt ratio. Beijing SL Pharmaceutical Co Ltd (002038) has a Cash Flow-to-Debt Ratio of 0.20x as of September 2025, meaning its operating cash flow of CN¥66.55 Million could theoretically repay 0% of its total liabilities (CN¥327.96 Million) in one year. Check how high is Beijing SL Pharmaceutical Co Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Beijing SL Pharmaceutical Co Ltd (2003–2025)
Cash flow-to-debt ratio of Beijing SL Pharmaceutical Co Ltd from 2003 to 2025. Historical debt coverage capacity for Beijing SL Pharmaceutical Co Ltd across 23 annual periods. Check 002038 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Beijing SL Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio by Year (2003–2025)
Beijing SL Pharmaceutical Co Ltd cash flow-to-debt ratio by year from 2003 to 2025. Year-by-year debt coverage analysis for Beijing SL Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see Beijing SL Pharmaceutical Co Ltd cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.29x | CN¥257.66 Million | CN¥883.49 Million | ▼ -48.5% |
| 2024 | 0.57x | CN¥225.49 Million | CN¥398.37 Million | ▼ -42.5% |
| 2023 | 0.98x | CN¥460.20 Million | CN¥467.72 Million | ▲ +0.1% |
| 2022 | 0.98x | CN¥389.82 Million | CN¥396.60 Million | ▼ -8.1% |
| 2021 | 1.07x | CN¥464.63 Million | CN¥434.23 Million | ▲ +5.5% |
| 2020 | 1.01x | CN¥415.84 Million | CN¥410.09 Million | ▼ -38.5% |
| 2019 | 1.65x | CN¥665.83 Million | CN¥403.76 Million | ▲ +59.7% |
| 2018 | 1.03x | CN¥485.17 Million | CN¥469.73 Million | ▼ -22.5% |
| 2017 | 1.33x | CN¥380.72 Million | CN¥285.67 Million | ▼ -49.2% |
| 2016 | 2.62x | CN¥396.86 Million | CN¥151.19 Million | ▼ -22.8% |
| 2015 | 3.40x | CN¥504.87 Million | CN¥148.40 Million | ▲ +0.9% |
| 2014 | 3.37x | CN¥465.00 Million | CN¥137.92 Million | ▲ +19.5% |
| 2013 | 2.82x | CN¥347.41 Million | CN¥123.09 Million | ▼ -25.5% |
| 2012 | 3.79x | CN¥398.60 Million | CN¥105.17 Million | ▼ -16.2% |
| 2011 | 4.53x | CN¥228.59 Million | CN¥50.52 Million | ▼ -29.3% |
| 2010 | 6.40x | CN¥238.13 Million | CN¥37.22 Million | ▲ +34.8% |
| 2009 | 4.75x | CN¥174.41 Million | CN¥36.75 Million | ▼ -36.7% |
| 2008 | 7.50x | CN¥194.32 Million | CN¥25.91 Million | ▲ +194.6% |
| 2007 | 2.55x | CN¥88.36 Million | CN¥34.71 Million | ▲ +56.6% |
| 2006 | 1.63x | CN¥57.55 Million | CN¥35.41 Million | ▼ -19.8% |
| 2005 | 2.03x | CN¥47.48 Million | CN¥23.42 Million | ▲ +84.0% |
| 2004 | 1.10x | CN¥31.26 Million | CN¥28.38 Million | ▲ +32.6% |
| 2003 | 0.83x | CN¥30.55 Million | CN¥36.78 Million | — |